DZD, an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the recent completion of a $16M round of financing. This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.
San Diego, CA November 1 – 5 For more information please visit SITC’s website.
San Diego, CA November 1 – 5 For more information please visit SITC’s website.
Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, CA — October 18, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today […]
Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, CA — October 18, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today […]